An article in Nature Reviews Drug Discovery contends compensation for clinical trial subjects “is badly overdue” and stakeholders, including patients, who make up the research ecosystem need to come to consensus on the issue. The July 18 Comment urged “policymakers, regulators and, especially, industry sponsors to end underpayment for research participants. Moreover, we implo... Read More